The BRCA genes (BRCA1 and BRCA2) are also normally involved in a different pathway of DNA repair, and mutations in those genes can block that pathway. By blocking the PARP pathway, olaparib makes it very hard for tumor cells with a BRCA gene that doesn’t work to repair damaged DNA, which often leads to the death of these cells.